Fed. Circ. Revives Boehringer Diabetes Drug Patent

By Tiffany Hu (March 16, 2020, 9:48 PM EDT) -- The Federal Circuit on Monday reversed a lower court decision invalidating a Boehringer patent on a method of treating Type 2 diabetes that was asserted against Mylan and Aurobindo, ruling that the lower court erred in finding the patent covered an abstract idea....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!


Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!